Yogen Saunthararajah

Summary

Affiliation: University of Illinois at Chicago
Country: USA

Publications

  1. ncbi HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome
    Yogen Saunthararajah
    University of Illinois at Chicago, USA
    Blood 100:1570-4. 2002
  2. ncbi Decitabine and sickle cell disease: molecular therapy for a molecular disease
    Yogen Saunthararajah
    University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Pediatr Hematol Oncol 24:465-8. 2007
  3. ncbi Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
    Y Saunthararajah
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 112:195-200. 2001
  4. ncbi Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease
    Yogen Saunthararajah
    Section of Hematology Oncology, University of Illinois at Chicago, Chicago, IL 60607 7173, USA
    Semin Hematol 41:11-6. 2004
  5. ncbi Combinatorial action of RUNX1 and PU.1 in the regulation of hematopoiesis
    Yogen Saunthararajah
    Department of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, IL 60612, USA
    Crit Rev Eukaryot Gene Expr 16:183-92. 2006
  6. ncbi Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease
    Yogen Saunthararajah
    University of Illinois at Chicago, Section of Hem Onc, MBRB Rm 3150 MC734, 900 S Ashland Ave, Chicago, IL 60607, USA
    Blood 102:3865-70. 2003
  7. ncbi A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
    Yogen Saunthararajah
    University of Illinois at Chicago, MBRB rm3150 MC734, 900 S Ashland Ave, Chicago, IL 60607, USA
    Blood 102:3025-7. 2003
  8. ncbi DNA hypo-methylating agents and sickle cell disease
    Yogen Saunthararajah
    University of Illinois at Chicago, 900 S Ashland Avenue, Chicago, IL 60607 7173, USA
    Br J Haematol 126:629-36. 2004
  9. ncbi RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function
    Donglan Li
    Department of Medicine, University of Illinois, Chicago, Illinois 60612, USA
    J Biol Chem 282:13542-51. 2007
  10. ncbi HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders
    Minoo Battiwalla
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 123:449-53. 2003

Collaborators

Detail Information

Publications27

  1. ncbi HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome
    Yogen Saunthararajah
    University of Illinois at Chicago, USA
    Blood 100:1570-4. 2002
    ..008). In MDS with RA, DR15 may be useful as a guide to pathophysiology, prognosis, and treatment...
  2. ncbi Decitabine and sickle cell disease: molecular therapy for a molecular disease
    Yogen Saunthararajah
    University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Pediatr Hematol Oncol 24:465-8. 2007
  3. ncbi Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
    Y Saunthararajah
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Br J Haematol 112:195-200. 2001
    ..The lower response rate of MDS or T-LGL/MDS to immunosuppression, compared with T-LGL alone, may reflect the older age and intrinsic stem cell abnormalities in MDS and T-LGL/MDS patients...
  4. ncbi Clinical studies with fetal hemoglobin-enhancing agents in sickle cell disease
    Yogen Saunthararajah
    Section of Hematology Oncology, University of Illinois at Chicago, Chicago, IL 60607 7173, USA
    Semin Hematol 41:11-6. 2004
    ..Larger studies are required to confirm the safety and effectiveness of decitabine with chronic use, and to more clearly establish its role in patients with SCD...
  5. ncbi Combinatorial action of RUNX1 and PU.1 in the regulation of hematopoiesis
    Yogen Saunthararajah
    Department of Medicine and Cancer Center, University of Illinois at Chicago, Chicago, IL 60612, USA
    Crit Rev Eukaryot Gene Expr 16:183-92. 2006
    ..Here we describe the relationship of RUNX1 with PU.1 as a facet of the combinatorial relationships that determine hematopoietic lineage commitment...
  6. ncbi Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease
    Yogen Saunthararajah
    University of Illinois at Chicago, Section of Hem Onc, MBRB Rm 3150 MC734, 900 S Ashland Ave, Chicago, IL 60607, USA
    Blood 102:3865-70. 2003
    ..Chronic dosing and sustained increases in hemoglobin F and total hemoglobin levels may be possible. Further studies in SSD and thalassemia are indicated...
  7. ncbi A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
    Yogen Saunthararajah
    University of Illinois at Chicago, MBRB rm3150 MC734, 900 S Ashland Ave, Chicago, IL 60607, USA
    Blood 102:3025-7. 2003
    ..The ability of this system to predict response was confirmed in a separate cohort of 23 patients with MDS treated with immunosuppression...
  8. ncbi DNA hypo-methylating agents and sickle cell disease
    Yogen Saunthararajah
    University of Illinois at Chicago, 900 S Ashland Avenue, Chicago, IL 60607 7173, USA
    Br J Haematol 126:629-36. 2004
    ..Pharmacologic reactivation of HbF through DNA hypomethylation holds promise as an effective disease modifying intervention for patients with SSD. Larger studies are required to confirm safety and effectiveness with chronic use...
  9. ncbi RUNX1-RUNX1 homodimerization modulates RUNX1 activity and function
    Donglan Li
    Department of Medicine, University of Illinois, Chicago, Illinois 60612, USA
    J Biol Chem 282:13542-51. 2007
    ....
  10. ncbi HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders
    Minoo Battiwalla
    Hematology Branch, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Br J Haematol 123:449-53. 2003
    ..We conclude that CSA is effective in inducing haematological responses in HLA-DR4-positive patients and that T-LGL is likely to have an immune pathogenesis...
  11. ncbi Effect of AGM and fetal liver-derived stromal cell lines on globin expression in adult baboon (P. anubis) bone marrow-derived erythroid progenitors
    Donald Lavelle
    Department of Medicine, University of Illinois at Chicago, Chicago, Illinois, United States of America
    PLoS ONE 7:e36846. 2012
    ..We conclude that γ-globin expression in adult-derived erythroid cells can be influenced by the micro-environment, suggesting new potential targets for HbF induction...
  12. ncbi S110, a novel decitabine dinucleotide, increases fetal hemoglobin levels in baboons (P. anubis)
    Donald Lavelle
    Department of Medicine, University of Illinois at Chicago, 840 S, Wood St, Chicago, Illinois 60612 7323, USA
    J Transl Med 8:92. 2010
    ..In these experiments the effect of S110 on HbF levels in baboons and its ability to reduce DNA methylation of the γ-globin gene promoter in vivo were evaluated...
  13. ncbi Oral decitabine reactivates expression of the methylated gamma-globin gene in Papio anubis
    Donald Lavelle
    Jesse Brown VA Medical Center, Chicago, Illinois 60612, USA
    Am J Hematol 82:981-5. 2007
    ....
  14. ncbi Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine
    Donald Lavelle
    Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Blood 119:1240-7. 2012
    ..Combining oral THU with oral DAC changes DAC pharmacology in a manner that may facilitate accessible noncytotoxic DNMT1-targeted therapy...
  15. ncbi EVI1 induces myelodysplastic syndrome in mice
    Silvia Buonamici
    Department of Pathology and Cancer Center, University of Illinois at Chicago, Chicago, Illinois, USA
    J Clin Invest 114:713-9. 2004
    ..These defects are not fatal, and the mice survive for about 10 months with compensated hematopoiesis. Over this time, compensation fails, and the mice succumb to fatal peripheral cytopenia...
  16. ncbi Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes
    Jeffrey J Molldrem
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland 70892, USA
    Ann Intern Med 137:156-63. 2002
    ..Almost half of the deaths that result from myelodysplastic syndromes are due to cytopenia associated with bone marrow failure. Treatment is mostly supportive care...
  17. ncbi Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A
    Mohammed Milhem
    Section of Hematology/Oncology, University of Illinois Cancer Center, University of Illinois College of Medicine, Chicago, IL 60607, USA
    Blood 103:4102-10. 2004
    ..Our findings demonstrate that 5azaD and TSA can be used to alter the fate of primitive HSCs/HPCs during in vitro culture...
  18. ncbi Pathologic quiz case: a 68-year-old man with thrombocytosis and ringed sideroblasts. Essential thrombocythemia with ringed sideroblasts
    Jigna C Jani
    Department of Pathology, University of Illinois, Chicago 60612, USA
    Arch Pathol Lab Med 128:815-6. 2004
  19. ncbi Differentiation impairment and the evolution of MDS
    Nadim Mahmud
    Section of Hematology/Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
    Leuk Lymphoma 48:1267-8. 2007
  20. ncbi Patient-reported outcomes: descriptors of nociceptive and neuropathic pain and barriers to effective pain management in adult outpatients with sickle cell disease
    Diana J Wilkie
    Department of Biobehavioral Health Science, College of Nursing, MC 802, University of Illinois at Chicago, 845 S Damen Ave, Rm 660, Chicago, IL 60612 7350, USA
    J Natl Med Assoc 102:18-27. 2010
    ..Importantly, their pain may be both nociceptive and neuropathic, contrary to common expectations that SCD pain is only nociceptive. Few patients, however, took drugs effective for neuropathic pain...
  21. ncbi AML1-ETO decreases ETO-2 (MTG16) interactions with nuclear receptor corepressor, an effect that impairs granulocyte differentiation
    Vinzon Ibanez
    Section of Hematology Oncology, Department of Medicine, University of Illinois, Chicago, USA
    Cancer Res 64:4547-54. 2004
    ..In conclusion, decreasing interactions between ETO-2 and N-CoR, an effect of AML1-ETO, inhibits granulocyte differentiation...
  22. ncbi Standard clinical practice underestimates the role and significance of erythropoietin deficiency in sickle cell disease
    Santosh Saraf
    Department of Medicine, University of Illinois, Chicago Center for Clinical and Translational Research, University of Illinois, Chicago, IL, USA
    Br J Haematol 153:386-92. 2011
    ..In SCD patients, this standard approach can miss a substantial risk factor for early death. chRR could be a practical and important criterion for diagnosis of erythropoietin deficiency in SCD...
  23. ncbi Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment
    Martin H Steinberg
    Boston University School of Medicine, Center of Excellence in Sickle Cell Disease, Boston Medical Center, Boston, Mass 02118, USA
    JAMA 289:1645-51. 2003
    ..Hydroxyurea increases levels of fetal hemoglobin (HbF) and decreases morbidity from vaso-occlusive complications in patients with sickle cell anemia (SCA). High HbF levels reduce morbidity and mortality...
  24. ncbi DNA methylation and mechanism of action of 5-azacytidine
    Donald Lavelle
    Blood 111:2485; author reply 2486. 2008
  25. ncbi Clinical effectiveness of decitabine in severe sickle cell disease
    Yogen Saunthararajah
    Br J Haematol 141:126-9. 2008
  26. ncbi Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia
    Kenneth I Ataga
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB no 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27599 7305, USA
    Blood 111:3991-7. 2008
    ..This study is registered at http://clinicaltrials.gov as NCT00040677...
  27. ncbi Normal and transforming functions of RUNX1: a perspective
    Fady M Mikhail
    Department of Genetics, University of Alabama at Birmingham, Birmingham, Alabama, USA
    J Cell Physiol 207:582-93. 2006
    ..Here, we provide an overview of the many roles of RUNX1 in hematopoietic self-renewal and differentiation and summarize the information that is currently available on the many mechanisms of RUNX1 deregulation in human leukemia...